
ABOUT DASH BIO
Dash Bio is a CRO on a mission to accelerate the process by which drugs are developed. Traditional bioanalysis is slow, manual and error‑prone. Dash changes the equation as the only tech-first bioanalysis partner, putting both speed and quality at the forefront. Processing every sample on an automated platform, they eliminate variability and delays, delivering high quality, GLP-compliant results for preclinical and clinical studies in days, not months. Dash provides ELISA/MSD, LC‑MS and qPCR assays across a wide range of biomatrices, sample prep methods and customization options, enabling sponsors to move from insight to action, faster. Co-founded by industry veterans who understand the pain of the traditional CRO model, Dash's model prioritizes transparency, publishing pricing upfront and backing every project with guaranteed timelines and outcomes.
FEATURED ARTICLES
-
In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional—it is essential to survival and success.
-
Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.
-
Bioanalysis remains one of the most persistent bottlenecks in drug development, with CRO's displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
CONTACT INFORMATION
Dash Bio
56 Broad St STE 14011
Boston, MA 02109
UNITED STATES
Phone: 617-249-4472
Contact: Ander Tallett
FEATURED SOLUTIONS
-
Move drug development into the modern era with a CRO that offers assay development and validation, bioanalytical testing, sample prep, and more.